Futura Medical PLC
24 September 2026
The following amendment has been made to the 'Result of General Meeting and Total Voting Rights' announcement released on 24/09/26 at 10:36 under RNS No 1721.
The amendment relates to the Retail Offer Shares figure, which should read 100,000,000. All other details remain unchanged.
The full amended text is shown below.
24 September 2026
Futura Medical plc
("Futura", "the Company" or “the Group”)
Result of General Meeting and Total Voting Rights
Futura Medical (AIM:FUM), the consumer healthcare group behind Eroxon®, that specialises in the development and global commercialisation of innovative and clinically proven sexual health products, announces that following the General Meeting held on 23 September 2026 at the offices of Panmure Liberum, 25 Ropemaker Street, London EC2Y 9LY at 10:00 a.m., all resolutions set out in the notice of General Meeting contained in the Circular dated 4 September 2026 were duly passed.
Resolutions 1 and 3 were proposed as ordinary resolutions and resolutions 2, 4 and 5 were proposed as special resolutions. The total number of votes received on each resolution were as follows:
|
|
For |
Against |
|
|
||
|
Resolution |
Votes For |
% of votes cast |
Votes Against |
% of votes cast |
Votes withheld |
Total votes cast |
|
1 |
86,354,516 |
97.05 |
2,629,309 |
2.95 |
747,805 |
88,983,825 |
|
2 |
86,289,880 |
97.00 |
2,667,548 |
3.00 |
774,202 |
88,957,428 |
|
3 |
86,291,292 |
97.09 |
2,585,822 |
2.91 |
854,516 |
88,877,114 |
|
4 |
86,334,169 |
96.99 |
2,677,612 |
3.01 |
719,849 |
89,011,781 |
|
5 |
86,343,483 |
96.99 |
2,675,631 |
3.01 |
712,516 |
89,019,114 |
Accordingly, all conditions precedent relating to the proposed placing, subscription and retail offer (the “Fundraise”) announced on 3 September 2026 have now been met (save for Subsequent Admission).
Application has been made for 23,500,000 Subscription Shares, 719,367,225 Conditional Placing Shares and 100,000,000 Retail Offer Shares to be admitted to trading on AIM, it is expected that the admission will become effective and that dealings will commence at 8.00 a.m. on or around 25 September 2026.
Total Voting Rights
Following the Admission, the Company will have 1,482,327,755 ordinary shares of £0.002 each in issue.
The Company does not hold any shares in treasury and all of the Ordinary Shares have equal voting rights. Therefore, the figures above represent the total voting rights in the Company and this figure may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the voting rights of the Company under the FCA's Disclosure Guidance and Transparency Rules
Unless otherwise stated, capitalised termsnot otherwise defined in the text ofthis announcement have the same meanings ascribed to them as in the announcement released by the Company on 3 September 2026.
- ENDS –
Contacts:
|
Futura Medical plc
|
Alexander Duggan Chief Executive Officer Angela Hildreth Finance Director and COO
|
investor.relations@futuramedical.com +44 (0)1483 685 670
|
|
Panmure Liberum Nominated Adviser and Joint Broker |
Emma Earl, Will Goode, Mark Rogers (Corporate Finance)
|
+44 (0) 20 3100 2000
|
|
|
|
|
|
Turner Pope Investments (TPI) Ltd -Joint Broker and Retail Offer Coordinator |
Guy McDougall, Andrew Thacker |
+44 (0) 20 3657 0050 |
|
|
|
|
|
Alma Strategic Communications |
Rebecca Sanders-Hewett, Sam Modlin, Sarah Peters |
+44 (0) 20 3405 0205 futura@almastrategic.com |
Notes to Editors:
Futura Medical plc (AIM: FUM) is the developer of innovative, consumer-focused, sexual health products, including lead product Eroxon® and development projects WSD4000 and Eroxon® Intense. Our core strength lies in our research, development, regulatory and business development expertise in developing innovative, clinically proven, insight-led and effective products to support our customers in the growing sexual health market.
Sexual health issues are prevalent globally in both men and women. Erectile Dysfunction ("ED") impacts 1 in 5 men globally across all adult age brackets, with approximately half of all men over 40 experiencing ED and 25% of all new diagnoses being in men under 40. 60% of women experience at least one symptom of impaired sexual response or function in a twelve-month period, with only one in four women seeking professional help and remaining chronically underserved.
Eroxon®, Futura's clinically proven lead product, has been developed for the treatment of ED. The highly differentiated product, which is the only topical gel treatment for ED available over the counter and helps men get an erection fast, addresses significant unmet needs in the ED market. Multiple license or distribution partnerships are in place for Eroxon®, across major consumer markets.
WSD4000 is a project name for Futura's development female sexual health portfolio, starting with the creation of a range of topical gels under Futura's unique platform technology, specifically designed to treat symptoms of sexual dysfunction in women. There is currently no known regulatory approved OTC treatment available for impaired sexual response and function in women. WSD4000 has the potential to be an effective, breakthrough treatment for the common symptoms associated with impaired sexual response and function, such as lack of desire, arousal, lubrication, ability to orgasm and overall sexual satisfaction.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ENDRNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.